Mascoma, based in Boston, Massachusetts, USA, is a renewable fuels company that has developed the technology for the low cost conversion of biomass.
Utilising its proprietary consolidated bioprocessing technology platform, Mascoma developed bioengineered yeasts and other microorganisms to reduce costs and improve yields in the production of renewable fuels and chemicals. Mascoma is pursuing commercial applications of its CBP technology and is working with collaborators to develop and construct commercial scale facilities to convert hardwood pulpwood to cellulosic ethanol.
President and CEO William J. Brady, Jr. leads Mascoma’s management team. Brady joined the company in January 2010. From 2004 to 2009, Mr. Brady was Executive Vice President of Cabot Corporation, a specialty chemical company. He held many positions at Cabot in the United States and Japan, including General Manager of the Carbon Black business. Under his leadership, the business completed significant expansions in China and Brazil, and executed a major global initiative in energy efficiency. He is a graduate of the University of Scranton with a B.S. in Chemistry and received his M.B.A. from Fairleigh Dickinson University.
The research side is headed by Executive Vice President, Research & Development, Stephen R. Kennedy. Prior to joining Mascoma, he was at the Massachusetts Institute of Technology in Cambridge, Massachusetts from October 2010 to May 2011, where he held appointments in the Department of Chemical Engineering as Interim Executive Director of the Novartis/MIT Center for Continuous Manufacturing and in the Department of Biology/Center for Biomedical Innovation, where his responsibilities included scale-up of fungible fuel technology. Mr. Kennedy has also worked in the biopharmaceutical industry at Genzyme Corporation, or Genzyme, where he held senior positions in process development from 1992 to 1998, led development of manufacturing operations in the United States, France and Belgium from 1998 to 2004, and served as Senior Vice-President, Biologics Technical Operations from 2004 until 2010.